Abstract 2445: DNA recognition by XR5944, a novel bis-intercalator and potent anticancer drug

DNA is a major target for drugs used in cancer therapy. However, DNA interactive chemotherapeutics are limited by adverse effects due to their poor selectivity. The bis-phenazine compound XR5944 is a DNA bis-intercalator and potent anticancer drug which reached phase I clinical trials. The DNA binding mode and mechanism of XR5944 are unique, allowing it to recognize and bind the estrogen response element (ERE) sequence to inhibit ERα activity...